ROCKVILLE, Md., October 9, 2013 – MacroGenics, Inc., today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares of common stock are being offered by MacroGenics. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the same price to cover over-allotments, if any. The company’s shares are expected to begin trading on The NASDAQ Global Select Market on October 10, 2013 under the ticker symbol “MGNX”. The offering is expected to close on October 16, 2013, subject to customary closing conditions. BofA Merrill Lynch and Leerink Swann are acting as joint book-running managers for the offering. Stifel Nicolaus is acting as Lead Manager and Lazard Capital Markets and Wedbush Securities Inc. are acting as co-managers. A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on October 9, 2013. When available, copies of the final prospectus may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at firstname.lastname@example.org, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 4814, or by email at Syndicate@leerink.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. www.macrogenics.com